Alva Review-Courier -

FDA skeptical of benefits from experimental ALS drug

 

March 27, 2022



WASHINGTON (AP) — Federal health regulators issued a negative review Monday of a closely watched experimental drug for the debilitating illness known as Lou Gehrig's disease, after months of lobbying by patient advocates urging approval.

The drug from Amylyx Pharmaceuticals has become a rallying cause for patients with the deadly neurodegenerative disease ALS, their families and members of Congress who've joined in pushing the Food and Drug Administration to greenlight the drug.

But regulators said in a review that the company's small study was "not persuasive," due to missing data, error...



For access to this article please sign in or subscribe.

 

Reader Comments(0)

 
 

Our Family of Publications Includes:

Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2021

Rendered 08/13/2022 00:44